In comparison to the luminal subtypes, HER2+ BC has a higher proliferation rate, higher recurrence rate, and higher tendency to metastasize, with up to 30%–50% of HER2+ BC patients developing brain metastases (4). The gene discussed is ERBB2; the disease is breast cancer.